Coya Therapeutics Funding & Investors

Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s proprietary CTreg (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAITM (Exosomes Against Inflammation) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.